Clinical Trials Logo

Glaucoma, Suspect clinical trials

View clinical trials related to Glaucoma, Suspect.

Filter by:
  • Completed  
  • Page 1

NCT ID: NCT05686421 Completed - Glaucoma Clinical Trials

Comfortable and Stabilizing Chin & Forehead Rest Attachment for Slit Lamp Configurations

Start date: March 30, 2023
Phase: N/A
Study type: Interventional

In this study, participants will be imaged using two Optical Coherence Tomography (OCT) devices: device N, a standard conventional OCT device with an invention (comfortable chin and forehead rest that can be adjusted to fit each individual's size) attached to the device; and device C, the standard conventional OCT device with no invention attached. The investigators will assess whether the chin and forehead rest attachment (invention) provides a more comfortable experience for patients.

NCT ID: NCT04972695 Completed - Glaucoma Clinical Trials

Validation of an Automatic Analysis Algorithm of the Probability of Glaucoma From Optic Disc Images

Start date: May 7, 2021
Phase:
Study type: Observational

Clinical, cross-sectional and prospective study to assess the images of the posterior pole of the retina of patients from the Glaucoma Unit of the IOBA and the Hospital Clínico Universitario de Valladolid during the period between May and December 2021. The aim of the project is to provide a sufficient number of images from posterior pole retinographies in patients with suspected glaucoma or with diagnosis of glaucoma in order to determine the sensitivity and specificity of an automatic glaucoma screening algorithm developed by the company Transmural Biotech S.L.

NCT ID: NCT03978546 Completed - Glaucoma Clinical Trials

Diagnostic Performance of Smart Supra Perimetry (The DPSSP Study)

DPSSP
Start date: June 11, 2019
Phase: N/A
Study type: Interventional

Early glaucomatous visual field changes can be missed with the routinely used Standard Automated Perimetry (SAP) and the 24-2 test pattern due to limited sampling of the central 10 degrees. While this shortcoming can be overcome with the addition of a 10-2 test, performing both tests places extra demand on the perimetric services (doubling test times) and patients. Smart Supra Perimetry (SSP) uses a new faster algorithm that can complete both 24-2 and 10-2 test patterns in a similar time frame to a single 24-2 SAP test. This comparative study aims to determine the sensitivity and specificity (i.e. diagnostic accuracy) of SSP in identifying early glaucomatous visual field loss. A sample of 100 patients with early/suspect glaucoma will undergo SAP 24-2 and 10-2 (SITA algorithm) using Humphrey visual field perimetry and SSP 24+10-2 using Henson 9000. Eyes will be categorised into 2 groups i.e., glaucoma and non-glaucoma, on the basis of structural changes to the disc as evaluated by the clinician. The sensitivity and specificity of the SAP and SSP tests will be established along with test duration. The size and location of defects established with both the SAP and SSP strategies will also be compared.

NCT ID: NCT03534882 Completed - Ocular Hypertension Clinical Trials

Effects of Prostaglandin Analogue Washout Following Long-term Therapy in Adults With Primary Open Angle Glaucoma

Start date: May 27, 2014
Phase: N/A
Study type: Interventional

A target for glaucoma treatment is the intra-ocular pressure (IOP) which is lowered with medications, laser, or surgical intervention. The efficacy of different medication classes is well understood as their IOP lowering effects have been well documented. However, beyond the basic biochemical and pharmacokinetic actions, long-term effects of these drugs on IOP have not been adequately studied. Specifically, does long-term use of anti-glaucoma medications have lasting effects on IOP even with subsequent discontinuation of the medication? In Ontario, prostaglandin analogues are the most frequently prescribed first line anti-glaucoma medication. In our study, we examine the lingering IOP-reducing effects of the prostaglandin analogue anti-glaucoma drug class. Our overall objective is to determine if patients previously treated with prostaglandin analogues remain within acceptable treatment ranges 6 weeks after medication discontinuation, and if this IOP differs from pre-treatment baseline values. Half of participants will discontinue their prostaglandin analogue (PGA) treatment for 6 weeks, while the other half will continue their PGA therapy as prescribed by their ophthalmologist. Both groups will be followed closely throughout the 6 weeks to monitor changes in IOP. This can help us understand the lasting effects of medication use and can help better guide clinical care in optimizing glaucoma management, and help direct study designs of future research that involve any therapy secondary to prostaglandin analogue treatment.

NCT ID: NCT03318549 Completed - Glaucoma Clinical Trials

BCI and Evaluation of Visual and Task Performance in Subjects With Eye Diseases

Start date: October 29, 2018
Phase: N/A
Study type: Interventional

The purpose of this research study is to better understand the impact of visual impairment caused by different eye diseases on the ability to perform daily activities and compare it to that in patients without eye diseases.

NCT ID: NCT03014349 Completed - Glaucoma Suspect Clinical Trials

Water Drinking Test and Its Reproducibility in Goldmann Applanation Tonometry and Pneumatic Tonometry

WDTRGP
Start date: January 2016
Phase: N/A
Study type: Observational

The purpose of this study is to evaluate the reproducibility of tonometry in the Goldmann applanation apparatus and pneumatic in the water drinking test.

NCT ID: NCT02390245 Completed - Cataract Clinical Trials

Philadelphia Telemedicine Glaucoma Detection and Follow-Up Study

Start date: September 2014
Phase: N/A
Study type: Interventional

The goal is to conduct a 5-year prospective, randomized controlled trial to test an innovative, community-based intervention using posterior and anterior fundus photography of the optic nerve and macula and intraocular eye pressure measurements to improve access and utilization of eye care to detect, treat, and manage high-risk patients with previously undiagnosed glaucoma and other eye diseases. Research shows that subject failure to attend follow-up eye care appointments diminishes any previous benefits of community screenings for glaucoma. Greater adherence to follow-up visits can reduce glaucomatous blindness.